PL376673A1 - Białka fuzyjne mutein interferonu alfa o ulepszonych właściwościach - Google Patents

Białka fuzyjne mutein interferonu alfa o ulepszonych właściwościach

Info

Publication number
PL376673A1
PL376673A1 PL376673A PL37667304A PL376673A1 PL 376673 A1 PL376673 A1 PL 376673A1 PL 376673 A PL376673 A PL 376673A PL 37667304 A PL37667304 A PL 37667304A PL 376673 A1 PL376673 A1 PL 376673A1
Authority
PL
Poland
Prior art keywords
fusion proteins
improved properties
interferon alpha
alpha muteins
muteins
Prior art date
Application number
PL376673A
Other languages
English (en)
Inventor
Tim Jones
Matthew Baker
Marian Hanlon
Francis Joseph Carr
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL376673A1 publication Critical patent/PL376673A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL376673A 2003-02-18 2004-02-18 Białka fuzyjne mutein interferonu alfa o ulepszonych właściwościach PL376673A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03003647 2003-02-18

Publications (1)

Publication Number Publication Date
PL376673A1 true PL376673A1 (pl) 2006-01-09

Family

ID=32892853

Family Applications (1)

Application Number Title Priority Date Filing Date
PL376673A PL376673A1 (pl) 2003-02-18 2004-02-18 Białka fuzyjne mutein interferonu alfa o ulepszonych właściwościach

Country Status (11)

Country Link
US (1) US7456257B2 (pl)
EP (1) EP1594965A2 (pl)
JP (1) JP2007524351A (pl)
KR (1) KR20050107435A (pl)
CN (1) CN1751122A (pl)
AU (1) AU2004213565A1 (pl)
BR (1) BRPI0407533A (pl)
CA (1) CA2516293A1 (pl)
MX (1) MXPA05008704A (pl)
PL (1) PL376673A1 (pl)
WO (1) WO2004074486A2 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007000769A2 (en) * 2005-06-29 2007-01-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science RECOMBINANT INTERFERON α2 (IFNα2) MUTANTS
EP2200634B1 (en) 2007-09-21 2015-02-11 The Regents of The University of California Targeted interferon demonstrates potent apoptotic and anti-tumor activities
WO2010110503A1 (ko) * 2009-03-27 2010-09-30 주식회사 중외제약 인터페론-알파 및 세포질 잔류성 세포막 투과 펩타이드를 포함하는 IFN-α 융합 단백질
WO2011064758A2 (en) * 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
CA2851892C (en) 2011-10-28 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
EP2822575B1 (en) 2012-03-03 2020-05-06 ImmunGene, Inc. Engineered antibody-interferon mutant fusion molecules
US9803021B2 (en) 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
FI3677591T3 (fi) 2013-04-29 2023-04-03 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38-vasta-aineet ja fuusiot heikennetylle interferonille alfa-2b
EP2994754B1 (en) * 2013-05-10 2018-07-25 The United States of America, as represented by The Secretary, Department of Health and Human Services Compositions and methods for simultaneous detection of hcv antigen/antibody
US10093745B2 (en) 2013-05-29 2018-10-09 The Regents Of The University Of California Anti-CSPG4 fusions with interferon for the treatment of malignancy
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
KR102639037B1 (ko) 2014-10-29 2024-02-20 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 인터페론 α2b 변이체
WO2017123548A1 (en) * 2016-01-14 2017-07-20 Seattle Children's Hospital (dba Seattle Children's Research Institute) Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment
CN106065033A (zh) * 2016-03-17 2016-11-02 中国药科大学 一种细胞因子融合抗体的制备及其应用
EP3487522A4 (en) 2016-07-19 2020-04-01 Teva Pharmaceuticals Australia Pty Ltd ANTI-CD47 COMBINATION THERAPY
SG11202002533QA (en) 2017-09-22 2020-04-29 Kite Pharma Inc Chimeric polypeptides and uses thereof
CN111499718B (zh) * 2019-01-30 2022-06-14 复旦大学 人α干扰素受体结合相关位点突变体及其用途
US11136353B2 (en) 2019-04-15 2021-10-05 Qwixel Therapeutics Llc Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
WO1997033998A1 (en) * 1996-03-14 1997-09-18 The Immune Response Corporation Targeted delivery of genes encoding interferon
BR0010725A (pt) * 1999-05-19 2002-02-19 Lexigen Pharm Corp Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc
MXPA03007838A (es) * 2001-03-02 2003-12-08 Merck Patent Gmbh Interferon alfa modificado con inmunogenicidad reducida.
JP2005529170A (ja) * 2002-06-11 2005-09-29 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング Ｔ細胞エピトープをマッピングおよび除去する方法
US7611700B2 (en) * 2002-09-09 2009-11-03 Hanall Pharmaceuticals, Co., Ltd. Protease resistant modified interferon alpha polypeptides
WO2004031352A2 (en) * 2002-10-01 2004-04-15 Xencor, Inc. Interferon variants with improved properties

Also Published As

Publication number Publication date
WO2004074486A3 (en) 2005-03-31
US20070148739A1 (en) 2007-06-28
JP2007524351A (ja) 2007-08-30
BRPI0407533A (pt) 2006-02-14
CN1751122A (zh) 2006-03-22
US7456257B2 (en) 2008-11-25
MXPA05008704A (es) 2005-10-05
EP1594965A2 (en) 2005-11-16
KR20050107435A (ko) 2005-11-11
WO2004074486A2 (en) 2004-09-02
CA2516293A1 (en) 2004-09-02
AU2004213565A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
PL376673A1 (pl) Białka fuzyjne mutein interferonu alfa o ulepszonych właściwościach
HK1095765A1 (en) Interferon alpha antibodies and their uses
HUS1500024I1 (hu) GLP-1 analóg fúziós proteinek
EP1663278A4 (en) EPO MIMETIC PEPTIDES AND FUSION PROTEINS
PT1673460E (pt) Vacinas recombinantes e suas utilizações
IL166751A0 (en) Modified transferin-antibody fusion proteins
HK1095152A1 (en) Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof
AU2003239365A8 (en) Recombinant glycosyltransferase fusion proteins
IL176895A0 (en) Purified interleukin-15/fc fusion protein and preparation thereof
EP1581631A4 (en) INTERFERON VARIANTS HAVING IMPROVED PROPERTIES
IL207422A0 (en) Improved recombinant human interferon-beta-ib polypeptides
PL373052A1 (pl) Polipeptydy fuzyjne glikoprotein płytek IB alfa isposoby ich stosowania
PL363181A1 (pl) Zmodyfikowany interferon alfa o obniżonej immunogeniczności
IL172184A0 (en) Interferon gamma - like protein
PL375218A1 (pl) Zrekombinowane warianty białka
EP1687327A4 (en) NOVEL POLYPEPTIDES ASSOCIATED WITH THERMAL SHOCK PROTEIN 20 AND USES THEREOF
TWI350310B (en) Immunization of fish with plant-expressed recombinant proteins
AU2003272423A8 (en) Centrosome proteins and uses thereof
EP1842857A4 (en) MUTANT PROTEINS OF INTERFERON AND THEIR USE
EP1663110A4 (en) USES OF INTERFERONS WITH A MODIFIED SPATIAL STRUCTURE
AU2003282159A8 (en) Chimeric recombinant protein and in vitro diagnosis of hiv
EP1577322A4 (en) NEW PROTEINS AND THEIR USE
EP1541677A4 (en) NEW PROTEINS AND USE THEREOF
AU2003232176A8 (en) Protein c variants with altered properties
AU2003263751A8 (en) Novel proteins and their uses

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)